Abstract
The approval of monoclonal antibodies for therapy of hematologic malignacies (Rituxan®, Mylotarg™, Campath ®) renewed the interest in antibodies as potential new treatment options for cancer patients. Antibodies are effective in inhibiting tumor cell growth , inducing apoptosis, and activating host effector mechanisms for tumor cell killing. Monoclonal antibodies can be clinically effective as monotherapy, as targeting agents delivering either potent cytotoxic drugs or radionuclides as well as in combination with conventional chemotherapies. Advances in antibody engineering provided new capabilities to reduce immunogenicity, alter half life, increase effector functions, and increase tumor targeting for optimal therapeutic modalities requiring chronic dosing regimens. During the next decade, as new tumor-specific surface antigens are discovered and the linkage between genes and function is better understood, new targets will be identified for regulating tumor cell growth by engineered antibodies with agonist or antagonist activity. Additionally, antibody engineering will allow for more efficient radionuclide or cytotoxic drug targeting or lead to more selective activation of relevant host effector mechanisms, leading to a safe and effective therapy of cancer.
Current Pharmaceutical Biotechnology
Title: Future Approaches for Treating Hematologic Disease
Volume: 2 Issue: 4
Author(s): M. Reff, G. Braslawsky and N. Hanna
Affiliation:
Abstract: The approval of monoclonal antibodies for therapy of hematologic malignacies (Rituxan®, Mylotarg™, Campath ®) renewed the interest in antibodies as potential new treatment options for cancer patients. Antibodies are effective in inhibiting tumor cell growth , inducing apoptosis, and activating host effector mechanisms for tumor cell killing. Monoclonal antibodies can be clinically effective as monotherapy, as targeting agents delivering either potent cytotoxic drugs or radionuclides as well as in combination with conventional chemotherapies. Advances in antibody engineering provided new capabilities to reduce immunogenicity, alter half life, increase effector functions, and increase tumor targeting for optimal therapeutic modalities requiring chronic dosing regimens. During the next decade, as new tumor-specific surface antigens are discovered and the linkage between genes and function is better understood, new targets will be identified for regulating tumor cell growth by engineered antibodies with agonist or antagonist activity. Additionally, antibody engineering will allow for more efficient radionuclide or cytotoxic drug targeting or lead to more selective activation of relevant host effector mechanisms, leading to a safe and effective therapy of cancer.
Export Options
About this article
Cite this article as:
M. Reff , G. Braslawsky and N. Hanna , Future Approaches for Treating Hematologic Disease, Current Pharmaceutical Biotechnology 2001; 2 (4) . https://dx.doi.org/10.2174/1389201013378626
DOI https://dx.doi.org/10.2174/1389201013378626 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications
Current Cancer Drug Targets Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Hematologic Malignancies: Radiation Dosimetry Aspects
Current Pharmaceutical Biotechnology TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Subject Index
Current Drug Targets - Inflammation & Allergy Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy Promotion of Metastasis-associated Gene Expression in Survived PANC-1 Cells Following Trichostatin A Treatment
Anti-Cancer Agents in Medicinal Chemistry Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Targeting Rho GTPases by Peptidic Structures
Current Pharmaceutical Design